Galmed Pharmaceuticals Ltd. (NASDAQ:GLMD) announced the closing of its initial public offering of 3,263,010 ordinary shares at a public offering price of $13.50 per share, which included 425,610 ordinary shares issued upon the exercise in full of the underwriters’ option to purchase additional ordinary shares to cover over-allotments. Galmed Pharmaceuticals Ltd (NASDAQ:GLMD) stock performance was -1.58% in last session and finished the day at $10.93. Traded volume was 45,953.00million shares in the last session and the average volume of the stock remained 373.62K shares.
Recro Pharma, Inc. (NASDAQ:REPH), a clinical stage specialty pharmaceutical company developing non-opioid therapeutics for post-operative pain, today announced the appointments of Alfred F. Altomari and Dr. Michael Berelowitz to the Company’s Board of Directors. Recro Pharma Inc (NASDAQ:REPH) dropped -8.22 percent to $7.15 Thursday on volume of 95,756.00million shares. The intra-day range of the stock was $7.01 to $7.90. Recro Pharma Inc (NASDAQ:REPH) has a market capitalization of $51.09million.
BioTime, Inc. (NYSEMKT:BTX), a biotechnology company that develops and markets products in the field of regenerative medicine, today announced that Chief Executive Officer Michael D. West, PhD will present at the 2nd Annual Regen Med Investor Day to be held Wednesday, March 26, 2014 in New York City. BioTime, Inc. (NYSEMKT:BTX)’s stock on Mar 27, 2014 reported a decrease of -0.61% to the closing price of $3.24. Its fifty two weeks range is $3.21 -$4.82. The total market capitalization recorded $225.50million. The overall volume in the last trading session was 135,620.00million shares. In its share capital, BTX has 56.27million outstanding shares.
Shares of Onconova Therapeutics Inc (NASDAQ:ONTX) were the recipient of a large decrease in short interest in the month of January. As of February 28th, there was short interest totaling 1,272,556 shares, a decrease of 24.2% from the February 14th total of 1,679,370 shares, American Banking & Market News reports. On Thursday, shares of Onconova Therapeutics Inc (NASDAQ:ONTX) advanced 1.22% to close the day at $6.64. Company return on investment (ROI) is 14.10% and its monthly performance is recorded as -24.63%. Onconova Therapeutics Inc (NASDAQ:ONTX) quarterly revenue growth is -44.90%.